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Summary No published data are available concerning the activity and tolerability of intramuscularly
administered granulocyte colony-stimulating factor (G-CSF) in humans. To fill this gap, 19 patients with
advanced ovarian cancer previously treated with at least one first-line chemotherapy cycle received the
following myelosuppressive regimen: mitoxantrone (DHAD) 12 mg m-2 i.v. on day 1; ifosfamide (IFO)
4 g m-2 i.v. on days 1 and 2; mesna 800 mg m-2 i.v. t.i.d. on days I and 2. G-CSF (Filgrastim) was given at a
dose of 5 gLg/kg/day i.m. from day 6 to day 19, its pharmacokinetics being assessed in five patients. The
neutrophil nadir was observed after a mean period of 8 days, and the neutrophil count was <1.0 x I03 mm-3
for a mean of 6 days during the cycle of chemotherapy. The neutrophil count fell after the withdrawal of
G-CSF on the 19th day of treatment. The difference in absolute neutrophil count between day 19 and day 21
was statistically significant (P = 0.0001); nevertheless, at day 21 no WHO grade 3-4 neutropenia was reported.
DHAD and IFO were respectively given at 95% and 93% of the planned dose. The pharmacokinetics of
G-CSF i.m. seems to be similar to that of the drug given subcutaneously. No evidence of cumulative
myelosuppression was observed. G-CSF was well tolerated and no complications were observed at the
injection sites. In conclusion, if the results obtained in this pilot study regarding the activity of i.m. G-CSF are
confirmed by a randomised trial, the intramuscular administration of G-CSF could become a valid alternative
for patients who dislike the subcutaneous route and who are being treated with chemotherapy that does not
induce profound thrombocytopenia.
Ovarian cancer is the fourth most frequent cause of cancer
death in women, its incidence currently increasing by 19,000
new cases per year in the US (American Cancer Society,
1992). It has been estimated that approximately two-thirds of
the patients have stage III or IV disease at the time of initial
diagnosis (Young et al., 1989, p. 1166). In these cases, a
combined surgical/chemotherapeutic approach is considered
as standard treatment despite the fact that complete patho-
logical remission is observed in only about 20% of patients,
approximately half of whom will relapse (Ozols & Young,
1991). Consequently, most stage III-IV patients need a so
far unidentified second-line chemotherapy treatment, particu-
larly those who fail to benefit from first-line treatments with
platinum compounds.
As single agents, mitoxantrone (DHAD) and ifosfamide
(IFO) have already been tested as second-line treatments of
ovarian carcinoma, with encouraging results (Lawton et al.,
1987; Sutton et al., 1989); published data also support their
dose-response effect (Antman et al., 1990; Le Maistre &
Herzing, 1990). It therefore appeared appropriate to combine
full doses of both drugs in an attempt to identify an effective
second-line regimen for advanced ovarian cancer patients
resistant to platinum compound treatment, or relapsing after
it.
The well-known neutropenic effects of both drugs and the
previous first-line chemotherapy suggested the addition of
granulocyte colony-stimulating factor (G-CSF) in order to
reduce neutropenia levels and allow regular drug delivery.
G-CSF is a haematopoietic growth factor which, when sub-
cutaneously administered in phase II and III studies, has
been shown to reduce the incidence, duration and severity of
neutropenia, the total number of days of treatment with
intravenous antibiotics and the duration of hospitalisation.
Furthermore, G-CSF has proved to be clearly active in
reducing the incidence of fever with neutropenia and infec-
tions (Bronchud et al., 1989; Morstyn et al., 1989; Crawford
et al., 1991; Pettengell et al., 1992).
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No published data are yet available concerning the activity
and tolerability in humans of intramuscularly administered
G-CSF. Nevertheless, preclinical data suggest that G-CSF is
absorbed more rapidly after intramuscular than after sub-
cutaneous injection (Tanaka & Kaneko, 1991).
Furthermore, although no published data exist, intramus-
cular drug administration seems to be generally better
accepted by Italian patients than the subcutaneous route.
Given the characteristics of our patients, and the intensive
nature of the proposed regimen, this appeared to be an
appropriate opportunity for testing the intramuscular admin-
istration of G-CSF. The study was also extended to include
the assessment of drug pharmacokinetics in the last five
enrolled patients, and further evaluations were made in order
to relate G-CSF activity to the duration of chemotherapy.
Patients and methods
Eligibility criteria
The enrolled patients all had histologically confirmed ovarian
cancer, unamenable to surgery and previously treated with
one or more chemotherapy regimens containing platinum
compounds. The other baseline criteria were age between 18
and 60 years; an ECOG performance status of 0-1; the
absence of fever for more than 24 h before the start of
chemotherapy, with the discontinuation of all antibiotics; an
absolute neutrophil count (ANC) >2.0 x I03 mm-3, a plate-
let count > 150 x I03 mm-3, Hb > I0 g dl-; serum creatin-
ine <1.2mgl00ml-1 and creatinine clearance >,60ml
min-'; serum bilirubin <2.0mg 100ml-'; life expectancy
>3 months. Approval for the study was given by the local
ethical committee, and all of the patients gave their informed
consent. Concomitant cardiac disease as well as refractory or
recurrent cystitis were considered exclusion criteria. Con-
comitant or previous radiotherapy and the concomitant
administration of prophylactic antibiotics, cytokines, lithium
or white blood cell transfusions were not permitted.
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Treatment scheme
The chemotherapy consisted of DHAD 12mgm-2 i.v. bolus
on day 1, IFO 4gm-2 i.v. over 6h on days 1 and 2 and
mesna 800 mg m-2 i.v. bolus at 0, 4 and 6 h on days 1 and 2.
G-CSF i.m. was given at a dose of 5 pg/kg/day from day 6 to
day 19 inclusive. No early discontinuation or prolongation of
G-CSF was permitted. The cycles were repeated every 21
days.
G-CSF (Filgrastim) was supplied by Amgen as a clear,
colourless, sterile protein solution contained in 2 ml vials.
The withdrawable amount was 1.6 ml and the drug concen-
tration was 0.30mgml-'. The treatment was given in an
inpatient setting until the beginning of the second cycle;
thereafter, it was continued in an outpatient setting. G-CSF
was injected into one of the gluteus muscles by nurses in the
hospital, and thereafter by an assistant of the patients. The
patients were asked to return the used vials and to record the
times of administration in order to allow their compliance to
be checked. Furthermore, special attention was given to
inspecting injection sites when the patients were examined as
outpatients, in order to verify proper drug administration.
Response evaluations
Anti-tumour activity was evaluated by means of physical
examination and radiology, and the findings observed at
baseline and after three cycles of chemotherapy were com-
pared. Thereafter, the treatment was stopped in non-
responding patients; responders received two further cycles
(in no case was treatment continued for more than five
cycles). Patients with unmeasurable disease received five
cycles of chemotherapy unless clinically or radiologically
documented progressive disease was observed during treat-
ment.
Toxicity assessment and treatment modification
Side-effects, according to WHO criteria, were recorded by
asking patients to complete an appropriate form each time
they visited the outpatient clinic. Furthermore, physical
examination and complete blood chemistry were performed
every 3 weeks; complete blood counts were repeated three
times a week (i.e. eight times after each chemotherapy cycle).
No modification in the dosages of DHAD, IFO, mesna or
G-CSF was permitted. A delay of 1-2 weeks was adopted in
the case of myelosuppression at day 21 (i.e. ANC<2.0 x 103
mm 3, platelets <100 x 103 mm-3). After a maximum of 2
weeks' delay, patients with persistent myelosuppression were
withdrawn from the study. In the case of anaemia (Hb
<8gdl-1) at day 21, the patients received red blood cell
transfusions and, providing HB was >8 g dl-', the treatment
was continued.
Infections andfebrile neutropenia
Infections were diagnosed by clinical, radiological and
laboratory means, and treated according to standard proce-
dures. Febrile neutropenia was defined as a body temperature
> 38.20C and a concomitant ANC <1.0 x 103mmn3, with
no clinical, radiological or microbiological sign of specific
infection. Patients in whom febrile neutropenia was diag-
nosed were admitted to hospital whenever possible; in these
cases every effort was made to perform microbiological
examinations. Standard broad-spectrum antibiotic treatment
was started after microbiological examinations, and con-
tinued until the patient had become afebrile for more than
24h and the ANC was >1.0x 103mm-3.
G-CSFpharmacokinetics
Filgrastim kinetics was assessed in the last five patients
enrolled in the trial. Venous blood samples were obtained at
the beginning of the first cycle of G-CSF, at time 0 (before
G-CSF administration), and then 0.5, 1, 2, 4, 6, 8, 10, 16 and
24 h post dosing. Serum G-CSF concentrations were measur-
ed using a commercial ELISA kit obtained from R&R
Systems (Minneapolis, MN, USA). This assay is specific for
G-CSF and has a sensitivity limit of 0.08ngml-'.
The data were fitted using the non-linear least-squares
routine of RSTRIP software obtained from MicroMath
Scientific Software (Salt Lake City, UT, USA). From these
curve fits, the absorption phase half-life (t4Ka), terminal
phase half-life (tip) and maximum serum concentrations (tm.)
were obtained. AUC(I) was defined as the area under the
serum concentration vs time curve calculated by the trape-
zoidal rule to the last data point and extrapolated to infinity
by adding Cp(last)/P, where Cp(last) was the serum concentra-
tion at the last time point and ,B was obtained from the curve
fit. The mean residence time (MRT) was calculated using the
formula MRT = AUMC/AUC, where AUMC is the area
under the product of concentration and time vs time curve,
and AUC is the area under the serum concentration vs time
curve, with both curves extrapolated to infinity. CL/F was
defined as the systemic clearance rate (CL) divided by the
fraction of the absorbed dose (F) calculated using the for-
mula DOSE/AUC(I). CmaX was calculated as maximum serum
concentration obtained from the curve fit. VSS/F was the
volume of distribution at steady state divided by the
fraction of the dose absorbed calculated using the formula
MRT x CL/F.
Statistical analysis
This is a descriptive analysis and all of the data have been
given as percentages, means or medians, as appropriate.
Time to progression (TTP), overall survival (OS) and time to
the first occurrence of infection or febrile neutropenia were
estimated using the Kaplan-Meier time-to-event analysis.
The decrease in ANC between day 19 and day 21 was
evaluated using the Student t-test for paired data.
Results
Patients characteristics andadministered chemotherapy
Between July 1991 and December 1992, 19 patients were
enrolled in this single-centre pilot trial; all were evaluable in
terms of G-CSF activity and tolerability (i.e. all completed at
least one cycle of treatment). The characteristics of the
patients are reported in Table I. It should be emphasised that
4 of the 19 patients had received a second-line treatment
before study entry, and that ten had received one intensive
cisplatin first-line treatment with doses of 160 mgm2 every
21-28 days. A total of 72 cycles of DHAD plus IFO plus
G-CSF were administered (19 first cycles, 19 second cycles,
14 third cycles, 11 fourth cycles and nine fifth cycles), for a
median of four cycles per patient.
Table I Main patient characteristics
No. ofpatients
Entered/evaluable
Age
<50
50-60 years
Previous chemotherapy
Number of lines
1
2
Number of drugs
1
2
3
>3
Doses
Cisplatin high doses (160mg m-2 for 21 days)
Cisplatin standard doses
Duration
Mean number ofcycles (range)
19/19
10
9
19
4
12
5
1
10
9
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Variations in neutrophil levels and the incidence offebrile
neutropenia and infections
Including all 72 cycles, the mean time to neutrophil nadir
was 8 days, the mean nadir value being 0.2 x 103 mm-3 and
the mean nadir duration (until ANC> 1.0) being 5 days.
During one cycle of therapy (i.e. 21 days), the patients
showed ANC<1.0 x 103 mm-3 for a mean of 6 days; in no
case was ANC at day 21 <1.0 x 103 mm-3. During 7 of the
72 cycles, ANC did not fall below 1.0 x 103mm-3. The
median highest neutrophil value encountered was 20.0 x
103mm-3 (range 5.1-53.0), after a mean time of 18 days
from the start of the cycle. The changes in ANC for each
patient, and for all 72 cycles, are shown in Figure 1; the
curves were obtained by calculating median values for all
administered cycles.
Five episodes of infection with a mean duration of 5 days
(range 2-10) were reported in five different patients during
the 72 cycles of chemotherapy: pharyngitis in two patients,
and one case each of pneumonia, cystitis and pyodermitis.
All five patients recovered completely, and in none of them
was treatment withdrawn. Febrile neutropenia was diagnosed
during 10 of the 72 cycles, and had a mean duration of 6
days (range 1-10); in no case was treatment withdrawal
necessary because all ofthe patients recovered. During the 72
cycles as a whole, antibiotics were used for a mean time of
1.4 days per cycle.
Variations in neutrophil levels and the risk ofinfection and
febrile neutropenia in relation to treatment duration
Table II reports the time to nadir, nadir values and nadir
duration in relation to the number of administered cycles. As
can be seen, these data do not indicate any worsening of
neutropenia as treatment continued. On the contrary, except
for the fourth cycle, baseline ANC levels were higher for the
subsequent cycles than the first; furthermore, the duration of
neutropenia <1.0 x 103mm-3 was 7 days during the first
cycle vs 4 days during the fifth.
To analyse further the effect of treatment duration on
neutropenia and the risk of infection, the time to the first
episode of infection or febrile neutropenia was calculated for
all 19 patients (Figure 2). The Kaplan-Meier curve shows
that the probability of observing a first occurrence of infec-
tion or febrile neutropenia was higher during the first two
cycles of chemotherapy.
In order to verify the effect of continuation of treatment in
a more homogeneous patient population, the results reported
in Table II were analysed separately for the six patients who
ended the entire treatment programme without any delay. No
evidence of cumulative toxicity was observed; baseline ANC
was 2.8 before the first and 5.7 before the fifth cycle. Four
episodes of infection/febrile neutropenia were observed (one
pneumonia, three febrile neutropenia), all occurring during
the first two cycles ofchemotherapy (three at cycle no. 1, one
at cycle no. 2).
ANCmodifications immediately after G-CSFdiscontinuation
Figure 1 clearly shows that ANC fell after the withdrawal of
G-CSF on the 19th day of treatment. The difference in ANC
between day 19 and day 21 was statistically significant
(P = 0.0001; t = 4.93; d.f. = 18). In order to investigate the
tendency of neutrophil levels to fall after G-CSF withdrawal,
data were collected from eight patients in whom, for various
reasons, chemotherapy was delayed or withdrawn. In all of
these patients, an adequate follow-up of haematological
parameters was available for at least 1 week after the last
administration of G-CSF. The results are reported in Table
III. The median ANC values were 5.5 on the 21st day from
the beginning of the last chemotherapy cycle, 2.1 on day 28,
and 2.1 on day 35. Two of the eight patients had ANC
values of less than 2.0 on day 21 (the minimum value to
recycle), and these remained <2.0 until day 35. In both of
these patients, neutropenia persisted after treatment discon-
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Figure 1 ANCs during a treatment cycle. The solid line shows
the median values for all 72 cycles. The dotted lines show the
median values for each patient.
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Figure 2 Time to the first occurrence of infection or febrile
neutropenia (FUO) (number of patients at risk).
Table II Neutrophil nadirs according to treatment duration
Baseline ANC Time to nadir Nadir Nadir duration' Days x cycle with
Cycle (median) (mean) (mean) (mean) ANC<J,000 mm-3
no. (x 1,000mm-3) (days) (X 1,000mm-3) (days) (mean)
1 2.9 9 0.1 4 7
2 7.8 8 0.2 4 6
3 18.0 8 0.1 6 6
4 2.3 7 0.1 4 6
5 4.4 6 0.2 4 4
aUntil ANC> 1,000mm-3.
(9)
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tinuation and ANC returned to >2.0 only after 3 and 6
months. In the other six patients, ANC at day 21 was
adequate for recycling, but chemotherapy was delayed for
other reasons. However, in three of these patients, the ANC
fell below 2.0 at least once between day 21 and day 35, and
one 59-year-old patient had to be withdrawn from chemo-
therapy because the ANC was consistently less than 2.0 x 103
mm 3 between days 21 and 35 (ANC returned to >2.0 3
months after treatment discontinuation).
Treatment delays and withdrawals
The delays due to myelotoxicity are reported in Table IV. As
can be seen, only one of the 72 cycles was delayed because of
neutropenia. In this patient, the ANC at day 21 was ade-
quate for recycling and treatment was delayed for other
reasons; at day 28, the ANC was 1.2 x 103 mm-3 and, after a
further 1 week delay, neutrophils recovered and chemo-
therapy was repeated. Delays unrelated to myelotoxicity were
observed in two patients, for a total of four delayed cycles.
In one case, the patient refused to be treated every 3 weeks
for three consecutive cycles because of grade 2 asthenia; the
other patient did not receive the next cycle in time because of
the unavailability of a bed in the day hospital at the proper
time. Following the above-cited treatment delays, DHAD
was given at 95% of the planned dose (3.8-4mg m-2
Table III Modifications in ANC after G-CSF withdrawal
Patient's age Absolute neutrophil counta Cycle Previous
(years) Day 21 Day 28 Day 35 number treatments
41 20.0 1.2 4.4 4 PC (6)
48 1.4 1.2 1.8 3 PAC (7)
46 1.2 1.7 1.9 2 PCHD (5)
59 2.2 1.4 1.2 4 PAC (6)
57 30.0 3.2 NA 4 PCHD (5)
60 32.0 8.5 10.3 3 PCHD (6)
49 5.3 1.9 2.2 1 PCHD (5)
5.8 3.7 2.1 2
7.0 2.4 NA 3
60 3.4 3.4 NA 4 PC (7)
The number of cycles is given in parentheses. aValues x 103 mm-3.
PC, cisplatin+cyclophosphamide standard doses; PAC, cisplatin +
doxorubicin + cyclophosphamide standard doses; PCHD, cisplatin +
cyclophosphamide high doses (cisplatin 160mg m2 every 21 days);
NA, not applicable.
Table IV Treatment delays due to haematological toxicity
No. ofcycles/No. ofpatients
Administered 72/19
Delayed 3/3
Time ofdelay
One week 2
Two weeks 1
Delay related to treatment duration
Second cycles delayed
Third cycles delayed
Fourth cycles delayed
Fifth cycles delayed 3
Causes of delay
Neutrophil count <2,000 1
Hb values <8.0 2
week-') and IFO was given at 93% of the planned dose
(2.5-2.7 gm2 week-'). Treatment withdrawal due to hema-
tological toxicity occurred in three patients after the second,
third and fourth cycles. In all of these cases, the cause was
neutropenia (ANC<2.0 x 103 mm-3) persisting for a period
of at least 2 weeks after day 21. Seven-other patients discon-
tinued treatment (refusal because of grade 2 asthenia and
vomiting in two patients, a lack of anti-tumour response in
four patients and the onset of autoimmune thrombocyto-
penia in one). In this last case, anti-platelet antibodies were
discovered in the serum and the platelet count improved with
steroids.
A total of six patients ended the five planned cycles of
therapy without any treatment delay.
Side-effects related to G-CSF and to chemotherapy
Mild bone pain related to G-CSF was observed in 2 out of
19 patients and was reversed with paracetamol. In none of
the patients was any gluteal abscess, infection or flogosis
observed at the injection sites. Serum alterations of twice the
normal limits of alkaline phosphatase, lactate dehydrogenase
and uric acid were observed in respectively 13, eight and
three patients; however, these biochemical alterations had no
clinical implications. The intramuscular administration of G-
CSF did not cause any grade 3-4 toxicity.
Chemotherapy-related side-effects other than neutropenia
were also reported. Anaemia (Hb <1O g dl-1) was observed
in all 19 patients; in nine cases this was grade 3-4 (two cases
grade 4). Red blood cell transfusions were given during 12 of
the 72 cycles. No episodes of bleeding occurred and throm-
bocytopenia related to chemotherapy was reported in 2 of
the 19 patients (grade 2 in both cases); platelet transfusions
were not needed. No stimulatory effects of G-CSF on throm-
bocytopoiesis were observed. Other reported side-effects in
the 19 treated patients were nausea and vomiting (17
patients, grade 3 in two cases); alopecia (12 patients), cystitis
(eight patients), mucositis (three patients, grade 3 in one case)
and peripheral neurotoxicity (six patients). No treatment-
related deaths were observed.
Anti-tumour activity
Fourteen of the 19 patients had measurable disease at study
entry. Objective responses were observed in seven of these
patients (three complete responses), with a median duration
of 5 months (range 2-7+). Kaplan-Meier curves showed
that median TTP for the 19 patients was 7 months and
median OS 10 months.
Pharmacokinetics ofG-CSF
Table V reports the compartmental parameters obtained, and
Figure 3 shows the individual patient curve fits which corres-
pond to the parameters in Table V.
Discussion
Given subcutaneously, G-CSF has been shown to be effective
in reducing the risk of infection and in permitting the regular
administration of chemotherapy (Miller, 1993; Trillet-Lenoir
Table V Pharmacokinetic parameters from curve fits
Patient t4Ka tip t,. MRT AUC(I) CL/F Cm,, VSS/F
no. (hours) (hours) (hours) (hours) (ng h ml-') (mlmin-' kg-')(ngm-') (mlkg-')
15 1.61 4.23 3.69 8.43 149.3 0.56 12.5 283.2
16 2.52 4.69 5.21 10.41 220.7 0.38 15.9 237.2
17 2.29 3.51 4.30 8.36 262.1 0.32 24.1 160.5
18 2.43 3.37 4.72 8.37 405.5 0.21 37.7 105.5
19 5.02 7.35 9.33 17.85 379.7 0.22 17.2 235.6
Mean 2.77 4.63 5.45 10.68 283.5 0.34 21.5 204.4
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Figure 3 Individual patient curve fits (patients: 0, 15; 0, 16;
*, 17; 0, 18; A, 19).
et al., 1993). Whereas both the intravenous and subcutaneous
routes have been tested in clinical trials, no data have yet
been published concerning the activity and tolerability of
G-CSF given intramuscularly, although pharmacokinetic
data in rats are promising (Tanaka & Kaneko, 1991).
The combination of mitoxantrone and ifosfamide, both
myelosuppressive and given at full doses to patients already
treated with at least one first-line chemotherapy cycle,
appeared to be an appropriate regimen for testing the activity
of intramuscular G-CSF.
The preliminary pharmacokinetic data reported here show
that the time course of i.m. G-CSF seems to be similar to
that observed for subcutaneous administration (Morstyn et
al., 1989). This is important, since it is therefore likely that
similar ANC responses can be expected for the two routes.
Other data support the activity of G-CSF given intramus-
cularly. Indeed, a significant reduction in the ANC was
observed after G-CSF withdrawal at day 19 (P = 0.0001),
thus suggesting the efficacy of the i.m. route in stimulating
neutropoiesis. Furthermore, by comparing these data with
another ITMO trial (Bajetta et al., 1993), which evaluated
the same regimen at lower doses (DHAD 10 mgm-2 on days
1 and 21; IFO 4 g m-2 on days 1 and 21) in a similar patient
population, we can observe that at day 21 WHO grade 3-4
neutropenia did not occur in this study utilising G-CSF,
whereas it was detected in 16% of patients treated with the
lower doses without G-CSF. The more intensive regimen was
even more feasible in terms of dose intensity, DHAD being
given at 95% of the planned dose (vs 85% in the low-doses
trial) and IFO administration at 93% of the planned dose (vs
81%). Nevertheless, the data obtained by comparing two
different phase II trials must be taken with caution, and the
lack of a control arm in the present study means that these
observations can only be considered as preliminary; therefore
further confirmation is needed.
The intramuscular administration of G-CSF seems to be
well tolerated, and no complications at the injection sites
were observed. Nevertheless, it must be emphasised that our
chemotherapy did not induce profound thrombocytopenia;
otherwise the i.m. route might lead to the onset of complica-
tions at the injection site.
Our data suggest that there is no loss in G-CSF activity as
the chemotherapy continues. In this study it was observed
that, at the moment of recycling, the ANC generally in-
creases as the treatment progresses; furthermore, the number
of days with ANC <1.0 x 103 mm-3 was lower during the
fifth cycle than during the first, and a first occurrence of
infection or febrile neutropenia was encountered only during
the first two cycles. In relation to this, it has been postulated
that G-CSF might have a priming effect on the neutrophil
progenitor cells in the bone marrow of patients receiving
successive cycles (Trillet-Lenoir et al., 1993). However,
another possible explanation could lie in the fact that, as
only patients with good performance status receive the plan-
ned five cycles of chemotherapy, patient selection may
account for the lesser degree of neutropenia and infection
encountered in the fifth cycle. Nevertheless, it must be
emphasised that, even when the results were analysed in a
more homogeneous patient population (represented by the
six patients who ended the planned five cycles of chemo-
therapy without delays), no evidence of cumulative toxicity
was observed, and the first episode of infection or febrile
neutropenia was observed only during the first two cycles of
treatment.
The modification of ANC in the 2 weeks following G-CSF
discontinuation was also investigated. This acquires
significance in those patients who, for whatever reason, can-
not start another cycle at day 21 and in whom G-CSF
therapy was stopped some days before. Should G-CSF be
continued beyond the last planned day in such cases? Our
study design did not permit any early discontinuation or
prolongation of G-CSF, which was therefore given until day
19 even in patients who did not recycle at day 21. Two of
our patients were neutropenic (ANC <2.0) at day 21, and
the persistence of neutropenia for the next 2 weeks led to
treatment withdrawal. In these patients, it is reasonable to
hypothesise that G-CSF did not stimulate the bone marrow
in an adequate manner, and therefore prolongation of G-
CSF treatment beyond day 19 appears to be unjustified. In
the remaining six patients in whom this analysis was feasible,
we observed that ANC fell to <2.0 at least once between day
21 and day 35 in three cases, even if all three patients showed
ANC>2.0 at day 21. This determined treatment delays and
one withdrawal because of neutropenia. In these cases, the
further reduction in neutrophil count could be related to a
sort of 'rebound' effect (the stimulation of neutropoiesis
being followed by depression after G-CSF withdrawal), or it
may have been because the patients had received previous
chemotherapy before study entry (in some cases first-line
regimens were also intensive). In order to be able to support
one or other of these possibilities, it would have been useful
to have known bone marrow cellularity at the moment of
study entry. As it is, regardless of the cause determining the
further reduction in ANC, the question as to whether G-CSF
should have been continued beyond day 19 in these six
patients remains unanswered. In our opinion, it seems
reasonable to continue G-CSF beyond the last planned day
in those patients who reach day 21 with a normal ANC (even
ifclose to the limit) and who cannot receive another cycle for
reasons other than neutropenia. This was the case of the
59-year-old patient in whom chemotherapy was discontinued
because of neutropenia, despite the fact that the ANC at day
21 was 2.2.
In conclusion, intramuscularly administered G-CSF seems
to be well tolerated and might be active in stimulating
neutropoiesis. If a randomised trial, including a control arm,
confirms these results, the i.m. route could represent a valid
alternative for patients who dislike receiving G-CSF sub-'
cutaneously and who are recieving chemotherapy that does
not induce profound thrombocytopenia.
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